Valneva SE
VALNHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeValneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. The company carries a $533.9M market cap, placing it firmly in the small-cap category. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus.
Market Cap
$533.9M
Beta
—
P/E (TTM)
—
P/E (Fwd)
5.41
EPS (TTM)
$-1.86
EPS (Fwd)
$1.04
ROE
-109.6%
ROA
-14.5%
Cash
$105.3M
Total Debt
$209.5M
Free CF
-$31.0M
52W Change
-9.9%
Annual Financials
Cash vs Debt
The company holds $105.3M in cash, though total debt stands at $209.5M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company is burning cash, with free cash flow at -$31.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -109.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $361.3M to $174.7M.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Valneva SE and its sector.